TIRZEPATIDE VERSUS SEMAGLUTIDE: A COMPREHENSIVE REVIEW OF COMPARATIVE EFFICACY, SAFETY, AND METABOLIC OUTCOMES IN TYPE 2 DIABETES AND OBESITY
Abstract
Type 2 diabetes (T2D) and obesity represent chronic, escalating global health crises that necessitate potent pharmacological strategies. This comprehensive review compares the relative efficacy, safety, and overall metabolic benefits of tirzepatide (TZP), a novel dual GIP/GLP-1 receptor agonist, against semaglutide (SEMA), a selective GLP-1 receptor agonist. A systematic review was conducted, synthesizing data from 36 eligible Randomized Controlled Trials (RCTs), Indirect Treatment Comparisons (ITCs), and Real-World Evidence (RWE) studies involving adults with T2D and/or overweight/obesity. Key outcomes assessed included changes in HbA1c, body weight, and gastrointestinal adverse events (AEs). Findings from head-to-head RCTs (e.g., SURPASS-2) definitively demonstrated that all tested doses of once-weekly TZP (5 mg, 10 mg, and 15 mg) achieved statistically significantly greater reductions in both HbA1c and body weight compared to SEMA 1.0 mg. Furthermore, TZP significantly increased the proportion of participants achieving challenging composite endpoints, such as reaching stringent glycemic targets combined with substantial weight loss (e.g., ≥10%), without clinically significant hypoglycemia. ITCs comparing maximal doses also suggested that TZP 15 mg conferred superior efficacy for both weight and glycemic control over SEMA 2.4 mg in patients with T2D/obesity. The safety profile of TZP was generally consistent with the incretin class, characterized predominantly by transient gastrointestinal AEs (nausea, diarrhea, vomiting). In conclusion, tirzepatide, leveraging its dual GIP/GLP-1 agonism, provides consistently superior efficacy for glycemic control and body weight reduction compared to semaglutide, positioning dual incretin agonism as a powerful advance in treating T2D and obesity.
References
Al-Sabah, S., Al-Khairi, I., Jamal, M., Qaddoumi, M., Alajmi, F., Kumar, J., Abukhalaf, N., Cherian, P., Madhu, D., Arefanian, H., Dsouza, C., Alam-Eldin, N., AlSabagh, A., Al Madhoun, A., Al-Sabah, S., Al-Mulla, F., Abu-Farha, M., & Abubaker, J. (2024). Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 33(5), 478–490. https://doi.org/10.1159/000540534
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023). Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes, obesity & metabolism, 25(4), 961–964. https://doi.org/10.1111/dom.14940
Bahdi, F., Shah, S., Dahoud, F., Farooq, M., Kozan, P., Kim, S., Sedarat, A., Shen, N., Thaker, A., Kolb, J. M., Dutson, E., Muthusamy, V. R., & Issa, D. (2025). Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy. Clinical obesity, 15(3), e70001. https://doi.org/10.1111/cob.70001
Baser, O., Samayoa, G., Rodchenko, K., Isenman, L., Baser, E., & Yapar, N. (2024). The association between weight loss medications and cardiovascular complications. Obesity (Silver Spring, Md.), 32(7), 1401–1409. https://doi.org/10.1002/oby.24037
Bergman, B. K., Rosenstock, J., Garvey, W. T., Batterham, R. L., Chen, Y., Liu, M., Sharma, P., Karanikas, C. A., & Thieu, V. T. (2025). Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme. Diabetes, obesity & metabolism, 27(6), 3223–3232. https://doi.org/10.1111/dom.16337
Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of internal medicine, 10.7326/ANNALS-24-03609. Advance online publication. https://doi.org/10.7326/ANNALS-24-03609
Ciudin, A., Johansson, E., Zimner-Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J. F. (2025). Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes, obesity & metabolism, 27(9), 4709–4719. https://doi.org/10.1111/dom.16508
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025). Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?. Hypertension (Dallas, Tex. : 1979), 82(7), 1167–1174. https://doi.org/10.1161/HYPERTENSIONAHA.125.25112
Duhan, S., Kurpad, K. P., Keisham, B., Shtembari, J., Brener, A., Kanakadandi, U. B., Garg, A., Adoni, N. A., & Mehta, S. S. (2025). GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials. International journal of cardiology, 438, 133604. https://doi.org/10.1016/j.ijcard.2025.133604
Forst, T., De Block, C., Del Prato, S., Armani, S., Frias, J., Lautenbach, A., Ludvik, B., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2024). The role of incretin receptor agonists in the treatment of obesity. Diabetes, obesity & metabolism, 26(10), 4178–4196. https://doi.org/10.1111/dom.15796
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K., & SURPASS-2 Investigators (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
Gelhorn, H. L., Osumili, B., Brown, K., Ross, M. M., Schulz, A., Fernandez, G., & Boye, K. S. (2023). The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes. Patient preference and adherence, 17, 793–805. https://doi.org/10.2147/PPA.S401465
Go, C. C., Annie, F., Drabish, K., & Eslami, M. H. (2025). Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease. Journal of vascular surgery, 82(3), 1024–1032.e2. https://doi.org/10.1016/j.jvs.2025.05.037
Hankosky, E. R., He, X., Malik, R., Fraseur Brumm, J., Wang, F., Niemeyer, A., Zhang, X. M., & Garvey, W. T. (2025). Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, obesity & metabolism, 27(7), 3757–3765. https://doi.org/10.1111/dom.16401
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care, 46(5), 998–1004. https://doi.org/10.2337/dc22-1710
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., & Milicevic, Z. (2022). Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The lancet. Diabetes & endocrinology, 10(6), 418–429. https://doi.org/10.1016/S2213-8587(22)00085-7
Henney, A. E., Riley, D. R., Anson, M., Azmi, S., Alam, U., & Cuthbertson, D. J. (2025). Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver international : official journal of the International Association for the Study of the Liver, 45(10), e70367. https://doi.org/10.1111/liv.70367
Hoog, M. M., Vallarino, C., Maldonado, J. M., Grabner, M., Teng, C. C., Terrell, K., & Richard, E. L. (2025). Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders, 10.1007/s13300-025-01794-9. Advance online publication. https://doi.org/10.1007/s13300-025-01794-9
le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia-Perez, L. E., & Wharton, S. (2023). Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes, obesity & metabolism, 25(9), 2626–2633. https://doi.org/10.1111/dom.15148
Lingvay, I., Cheng, A. Y., Levine, J. A., Gomez-Valderas, E., Allen, S. E., Ranta, K., Torcello-Gómez, A., & Thieu, V. T. (2023). Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes, obesity & metabolism, 25(4), 965–974. https://doi.org/10.1111/dom.14943
Mather, K. J., Mari, A., Weerakkody, G., Heise, T., DeVries, J. H., Urva, S., Coskun, T., Milicevic, Z., Haupt, A., & Thomas, M. K. (2025). Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. Diabetes, obesity & metabolism, 27(3), 1507–1514. https://doi.org/10.1111/dom.16159
Mody, R. R., Meyer, K. L., Ward, J. M., & O'Day, K. B. (2023). Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States. Diabetes therapy : research, treatment and education of diabetes and related disorders, 14(12), 2045–2055. https://doi.org/10.1007/s13300-023-01470-w
Nicholls, S. J., Tofé, S., le Roux, C. W., D'Alessio, D. A., Wiese, R. J., Pavo, I., Brown, K., Weerakkody, G. J., Zeytinoglu, M., & Romera, I. C. (2024). Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program. Cardiovascular diabetology, 23(1), 63. https://doi.org/10.1186/s12933-024-02147-9
Niu, S., Alkhuzam, K. A., Guan, D., Jiao, T., Shi, L., Fonseca, V., Laiteerapong, N., Ali, M. K., Schatz, D. A., Guo, J., & Shao, H. (2024). 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine. Diabetes, obesity & metabolism, 26(2), 463–472. https://doi.org/10.1111/dom.15332
Osumili, B., Fan, L., Paik, J. S., Pantalone, K. M., Ranta, K., Sapin, H., & Tofé, S. (2024). Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison. Diabetes research and clinical practice, 212, 111717. https://doi.org/10.1016/j.diabres.2024.111717
Papantoniou, P., & Maniadakis, N. (2025). A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece. Healthcare (Basel, Switzerland), 13(16), 2011. https://doi.org/10.3390/healthcare13162011
Patel, H., Khunti, K., Rodbard, H. W., Bajaj, H. S., Bray, R., Kindracki, Z., & Rodríguez, Á. (2024). Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, obesity & metabolism, 26(2), 473–481. https://doi.org/10.1111/dom.15333
Reitzel, S. B., Bøgelund, M., Basse, A., Barszczewska, O., & Ren, H. (2023). Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates. Current medical research and opinion, 39(8), 1055–1060. https://doi.org/10.1080/03007995.2023.2231275
Scheen A. J. (2023). Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Annales d'endocrinologie, 84(2), 316–321. https://doi.org/10.1016/j.ando.2022.12.423
Tall Bull, S., Nuffer, W., & Trujillo, J. M. (2022). Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. Journal of diabetes and its complications, 36(12), 108332. https://doi.org/10.1016/j.jdiacomp.2022.108332
Tang, H., Lu, Y., Zhang, B., Zhou, T., Zhang, D., Chen, J., Chen, Y., Asch, D. A., & Chen, Y. (2025). Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes, obesity & metabolism, 27(11), 6527–6536. https://doi.org/10.1111/dom.70054
Toraih, E. A., Alenezy, A., Hussein, M. H., Hashmat, S., Mummadi, S., Alrawili, N. F., Abdelmaksoud, A., & Fawzy, M. S. (2025). The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort. Biomedicines, 13(5), 1049. https://doi.org/10.3390/biomedicines13051049
Trinh, H., Donovan, A., & McAdam-Marx, C. (2025). Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting. Diabetes, obesity & metabolism, 27(6), 3523–3525. https://doi.org/10.1111/dom.16343
Vadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., Pantalone, K. M., & Sapin, H. (2022). Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes, obesity & metabolism, 24(9), 1861–1868. https://doi.org/10.1111/dom.14775
Valentine, W. J., Hoog, M., Mody, R., Belger, M., & Pollock, R. (2023). Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes, obesity & metabolism, 25(5), 1292–1300. https://doi.org/10.1111/dom.14979
Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269–5279. https://doi.org/10.1111/dom.16580
Views:
0
Downloads:
0
Copyright (c) 2025 Marcin Schulz, Dawid Studziński, Anna Kołcz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
